Meningococcal Type B – Protecting Against the Most Common Cause of invasive meningococcal disease (IMD) in Canada (2022)
N. meningitidis serogroup B strain is the most prevalent form of invasive meningococcal disease in Canada. Although this infection is relatively rare, no other bacterial agent may kill as swiftly after bloodstream invasion as the meningococcus. With the availability of vaccines to protect against the different serogroups, it is important for clinicians to educate patients on the potential risks of meningococcal infection and the benefits of immunization. This program will review the clinical consequences of meningococcal type B infection, the different vaccine options and how it can be integrated into practice.
This program has received an unrestricted educational grant or in-kind support from GSK.
This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 1 Mainpro+ credits.
Mark Awuku, MB, ChB, FRCP(C), FAAP, FGCP, LLD (Honoris Causa)
Dale Ziter, MD, CCFP, FCFP
Suni Boraston, MD, MHSC
Vivien Brown, MDCM, CCFP, FCFP, NCMP
Christine Palmay, CCFP, FCFP
Upon completion of this continuing education program, participants will be better able to:
- Describe meningococcal disease burden and prevention, addressing the importance of MenB protection for infants as early as two months of age, children, and adolescents, addressing disease epidemiology, disease significance & severity
- Review the challenges to MenB vaccine development, the indications and modes of action
- Highlight the growing body of scientific evidence supporting MenB vaccination e.g. real-world experience, dosing schedules, persistence data, immunogenicity data spanning the age cohorts at risk of disease
- Practical implications for non-publicly funded vaccines in the clinical practice: how to discuss MenB vaccination, where it can fit into the routine childhood vaccination schedule, and how to address questions/objections from parents